Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
Lisa Licitra(University of Milan), Robert I. Haddad(Georgetown University), John Paul Shen(The University of Texas MD Anderson Cancer Center), Makoto Tahara(National Cancer Center Hospital East), Bogdan Żurawski, Shunji Takahashi(Japanese Foundation For Cancer Research), Karen O’Hara(Eisai (United States)), Andrew Z. Wang(Ocean NanoTech (United States)), Sercan Aksoy(Hacettepe University Hospital), Paul Swiecicki(University of Michigan), Tibor Csőszi, Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Yi Guo(Shanghai East Hospital), Tainá B. Oliveira(AC Camargo Hospital), Min Fang(Zhejiang University of Technology), Muh‐Hwa Yang(National Yang Ming Chiao Tung University), K.C. Benjamin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mikhail Klochikhin
International Journal of Radiation Oncology*Biology*Physics
March 14, 2024
Cited by 32
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k